Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591
This study is recruiting at 18 US sites in 15 states, according to its ClinicalTrials.gov record last updated .
Summary
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- NSCLC
- RAS Mutation
- MTAP Deletion
- Lung Cancer
- Pancreatic Cancer Metastatic
- Thoracic Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Tango Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- May 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic Scottsdale · Scottsdale, AZ
Colorado · 1
- Sarah Cannon Research Institute Denver · Denver, CO
District of Columbia · 1
- Georgetown University Medical Center · Washington D.C., DC
Florida · 1
- Mayo Clinic Jacksonville · Jacksonville, FL
Illinois · 1
- Northwestern Memorial Hospital · Chicago, IL
Indiana · 1
- University of Indiana · Indianapolis, IN
Iowa · 1
- University of Iowa Health Care · Iowa City, IA
Massachusetts · 2
- Dana-Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital · Boston, MA
Minnesota · 1
- Mayo Clinic Cancer Center · Rochester, MN
Nebraska · 1
- Nebraska Cancer Specialists · Omaha, NE
New York · 2
- Memorial Sloan Kettering Cancer Center · New York, NY
- NYU Langone Health · New York, NY
North Carolina · 1
- University of North Carolina at Chapel Hill · Chapel Hill, NC
Texas · 2
- University of Texas MD Anderson Cancer Center · Houston, TX
- NEXT Dallas · Irving, TX
Utah · 1
- Huntsman Cancer Institute, University of Utah · Salt Lake City, UT
Virginia · 1
- NEXT Oncology · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.